![]() | |
Clinical data | |
---|---|
Other names | LY 300502 |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H16ClNO |
Molar mass | 249.74 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride. [1] [2] It is selective for the type I isoform of the enzyme. [1] It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed. [3] [4]